• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 3
  • 2
  • Tagged with
  • 3
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

The role of p53 mutants in drug sensitivity of osteosarcoma Saos-2 cells. / CUHK electronic theses & dissertations collection

January 2001 (has links)
by Tsang Wing Pui. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (p. 195-215). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.
2

Clinical significance of plasma bone-specific alkaline phosphatase measurement and the alkaline phosphatase isozymes expression in osteosarcoma.

January 1997 (has links)
by Au Sze Ki. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1997. / Includes bibliographical references (leaves xii-xix). / Acknowledgement --- p.i / Table of Content --- p.ii / List of Abbreviation --- p.vi / Abstract --- p.viii / Chapter Chapter One : --- Introduction / Chapter 1.1. --- Osteosarcoma --- p.1 / Chapter 1.1.1. --- Definition --- p.1 / Chapter 1.1.2 --- "Incidence, geographic patterns of distribution and epidemiological consideration" --- p.1 / Chapter 1.1.3 --- "Age, sex and sites" --- p.3 / Chapter 1.1.4 --- Type and grade --- p.5 / Chapter 1.1.4.1. --- Grade --- p.5 / Chapter 1.1.4.2. --- Site --- p.5 / Chapter 1.1.4.3. --- Metastasis --- p.5 / Chapter 1.1.5 --- Histological features --- p.9 / Chapter 1.1.6 --- Clinical features --- p.9 / Chapter 1.1.7 --- Radiological features --- p.11 / Chapter 1.1.8. --- Molecuar genetics --- p.13 / Chapter 1.1.9 --- Treatment --- p.13 / Chapter 1.2 --- Biochemical Markers of Osteosarcoma --- p.14 / Chapter 1.2.1 --- Tumor marker --- p.14 / Chapter 1.2.2 --- Biochemical markers of bone turnover --- p.15 / Chapter 1.2.3 --- Change of biochemical marker in osteosarcoma --- p.17 / Chapter 1.3 --- Alkaline Phosphatase (ALP) --- p.17 / Chapter 1.3.1 --- ALPs Family --- p.20 / Chapter 1.3.2 --- Membrane binding --- p.22 / Chapter 1.3.3 --- Biochemical function and physiological role of ALP --- p.24 / Chapter 1.4 --- Normal values of serum ALP --- p.28 / Chapter 1.5 --- Clinical applications of ALP --- p.28 / Chapter 1.6 --- "Separation, identification and quantification of ALP isozymes" --- p.31 / Chapter 1.6.1 --- Themostability --- p.31 / Chapter 1.6.2 --- Inhibition studies --- p.31 / Chapter 1.6.3 --- Electrophoresis --- p.33 / Chapter 1.6.4 --- Isoelectric focusing --- p.34 / Chapter 1.6.5 --- Affinity precipitation --- p.34 / Chapter 1.6.6 --- Immunological studies --- p.35 / Chapter 1.7 --- Plasma BALP level as biochemical marker of osteosarcoma --- p.35 / Chapter 1.8 --- ALP in malignancies --- p.37 / Aim of study --- p.x / Chapter Chapter Two : --- Methods and Materials / Chapter 2.1 --- Plasma BALP measurement as a biochemical markerin osteosarcoma --- p.40 / Chapter 2.1.1 --- Patient groups --- p.40 / Chapter a) --- Normal subjects --- p.40 / Chapter b) --- Osteosarcoma patients --- p.40 / Chapter 2.1.2 --- Collection and preparation of patient bloods samples of patients --- p.40 / Chapter 2.1.3 --- Plasma total ALP measurement --- p.41 / Chapter a) --- Reagent --- p.41 / Chapter b) --- Procedure --- p.43 / Chapter 2.1.4 --- Plasma BALP measurements --- p.43 / Chapter a) --- Wheat germ lectin precipitation of BALP --- p.44 / Chapter i) --- Reagent / Chapter ii) --- Procedure / Chapter b) --- ABBOTT methods for plasma BALP activity measurement --- p.45 / Chapter c) --- COBAS MIRA methods for BALP measurement --- p.45 / Chapter d) --- ALKPHASE-B method of BALP measurement --- p.46 / Chapter 2.1.5 --- Inter-conversion of plasma BALP activity measurement in different methods --- p.47 / Chapter 2.1.6 --- Statistical analysis --- p.48 / Chapter 2.2 --- Alkaline phosphatase isozymes expression in human osteosarcoma --- p.48 / Chapter 2.2.1 --- In Vitro cultures of human SaOS-2 and U-2 OS osteosarcoma cell line --- p.48 / Chapter a) --- Reagent --- p.49 / Chapter b) --- Procedure --- p.50 / Chapter i) --- Storage of U-2 OS and SaOS-2 / Chapter ii) --- Subculture of confluent monolayer / Chapter 2.2.2 --- Protein assay --- p.51 / Chapter a) --- Standard Assay --- p.51 / Chapter i) --- Reagent / Chapter ii) --- Procedure / Chapter b) --- Mircoassay --- p.51 / Chapter i) --- Reagent / Chapter ii) --- Procedure / Chapter 2.2.3 --- Extraction of ALP from the cultured osteosarcoma cells --- p.52 / Chapter a) --- Reagent --- p.52 / Chapter b) --- Procedure --- p.52 / Chapter 2.2.4 --- "ALP extraction from human liver, placenta and osteosarcoma tissue" --- p.53 / Chapter a) --- Reagent --- p.53 / Chapter b) --- Procedure --- p.54 / Chapter 2.2.5 --- Isoelectric focusing of ALP --- p.55 / Chapter a) --- Preparation of the agarose IEF gel --- p.55 / Chapter b) --- Samples preparation --- p.56 / Chapter c) --- Isoelectric focusing --- p.57 / Chapter d) --- Protein detection --- p.59 / Chapter i) --- Reagent / Chapter ii) --- Procedure / Chapter e) --- Visualization of ALP isozyme --- p.60 / Chapter 2.2.6 --- Biochemical differentiation of ALP expressed in human osteosarcoma --- p.61 / Chapter a) --- Thermodenaturation of ALP --- p.61 / Chapter b) --- Ammino acid inhibition of ALP --- p.61 / Chapter 2.2.7 --- Immunohistostaining of placental ALP in human Osteosarcoma --- p.62 / Chapter a) --- Reagent --- p.62 / Chapter b) --- Preparation of human osteosarcoma cell line --- p.63 / Chapter c) --- Preparation of human osteosarcoma tissue --- p.63 / Chapter d) --- Immunohistostaining --- p.64 / Chapter Chapter Three : --- Results / Chapter 3.1 --- General information of the patients --- p.65 / Chapter 3.1.1 --- Age and sex distribution --- p.65 / Chapter 3.1.2 --- Sites --- p.65 / Chapter 3.1.3 --- Treatment and survival rate --- p.66 / Chapter 3.2 --- Clinical significance of plasma bone-specific alkaline phosphatase (BALP) activity measurementin osteosarcoma patients --- p.71 / Chapter 3.2.1 --- Plasma BALP activity measurement --- p.71 / Chapter 3.2.2 --- Normal reference of plasma BALP determination --- p.72 / Chapter 3.2.3 --- Diagnostic value of plasma BALP measurement in osteosarcoma --- p.75 / Chapter a) --- Plasma BALP level at admission --- p.75 / Chapter b) --- Plasma Total ALP level at admission --- p.78 / Chapter 3.2.4 --- Prognosis value of plasma BALP measurement in osteosarcoma Patients --- p.78 / Chapter a) --- Correlation of plasma BALP-Adm with the local relapse of the disease --- p.78 / Chapter b) --- Correlation of plasma BALP-Adm with survival rate of the patients --- p.90 / Chapter i) --- One year survival Rate / Chapter ii) --- two-year survival Rate / Chapter iii) --- Three-year survival rate / Chapter c) --- Correlation of the plasma BALP-Adm with the tumor volume --- p.90 / Chapter 3.2.5 --- Using plasma BALP measurement for monitoring of the disease --- p.91 / Chapter a) --- Effectiveness of pre-operative chemotherapy --- p.91 / Chapter b) --- Change of plasma BALP level during the treatment --- p.92 / Chapter i) --- Monitoring of pre-operative chemotherapy / Chapter ii) --- Detection of local recurrence and secondary metastasis / Chapter 3.3 --- Alkaline phosphatase isozyme expressionin osteosarcoma --- p.103 / Chapter 3.3.1 --- Isoelectric point (pI) gradient in isoelectric focusing (IEF)gel --- p.10? / Chapter 3.3.2 --- ALP isozyme standard --- p.103 / Chapter 3.3.3 --- Ectopic expression of ALP in human osteosarcoma cell line: U-2 OS and SaOS-2 --- p.104 / Chapter a) --- Isoelectric focusing separation --- p.104 / Chapter b) --- Biochemical differentiation of ALP extracts --- p.110 / Chapter 3.3.4 --- Alkaline phosphatase expression in osteosarcoma patient plasma sample --- p.110 / Chapter 3.3.5 --- Alkaline phosphatase isozyme expression in human osteosarcoma biopsy tissue --- p.111 / Chapter 3.3.6 --- Ectopic expression of placental ALP in human osteosarcoma by immunohistochemistry --- p.111 / Chapter a) --- Ectopic expression of placental ALP in human osteosarcoma cell line U-2 OS --- p.111 / Chapter b) --- Ectopic expression of placental ALP in human osteosarcoma tissue sections --- p.112 / Chapter Chapter Four : --- Discussion --- p.128 / Chapter Chapter Five : --- Conclusion --- p.142 / Bibliography --- p.xii / Appendix --- p.xx
3

Clinical application of adriamycin resistance screening and the in vitro effect of adriamycin on osteosarcoma cells.

January 1998 (has links)
by To Siu Hang. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 84-92). / Abstract also in Chinese. / Declaration --- p.i / Abstract --- p.ii / Acknowledgement --- p.vi / Abbreviations --- p.vii / List of Figures --- p.viii / List of Tables --- p.xii / Content --- p.xiv / Chapter 1. --- INTRODUCTION --- p.1 / Chapter 1.1. --- Osteosarcoma --- p.1 / Chapter 1.1.1. --- Incidence / Chapter 1.1.2. --- Age and Sex Distribution / Chapter 1.1.3. --- Clinical Features / Chapter 1.1.4. --- Treatment / Chapter 1.2. --- Adriamycin --- p.9 / Chapter 1.2.1. --- Drug Action / Chapter 1.2.2. --- Pharmacology / Chapter 1.3. --- Multidrug Resistance --- p.11 / Chapter 1.4. --- P-glycoprotein --- p.13 / Chapter 1.4.1. --- Nature / Chapter 1.4.2. --- Tissue Distribution / Chapter 1.4.3. --- Relation with MDR / Chapter 1.5 --- Multidrug Resistance Protein --- p.16 / Chapter 1.6. --- Reactive Oxygen Species --- p.17 / Chapter 1.6.1. --- Problems Arising from ROS / Chapter 1.6.2. --- Oxidative Stress and Diseases / Chapter 1.6.3. --- Defense System / Chapter 1.6.4. --- Antioxidative Enzymes / Chapter 1.6.5. --- Relation with MDR / Chapter 1.7. --- Topoisomerase II --- p.22 / Chapter 1.8. --- Methods to Detect MDR --- p.24 / Chapter 1.8.1. --- P-glycoprotein Immunohistochemistry / Chapter 1.8.2. --- Adriamycin Binding Assay / Chapter 1.9. --- Aims of Study --- p.25 / Chapter 2. --- MATERIALS AND METHODS --- p.27 / Chapter 2.1. --- Clinical Study --- p.27 / Chapter 2.1.1. --- Patients Recruitment / Chapter 2.1.2. --- Adriamycin Binding Assay / Chapter 2.1.3. --- P-glycoprotein Immunohistochemistry / Chapter 2.1.3.1. --- Sample and Control Preparation / Chapter 2.1.3.2. --- Immunohistochemical Procedure / Chapter 2.1.4. --- Tumour Necrosis Assessment / Chapter 2.2. --- Effect of Adriamycin on Osteosarcoma Cells --- p.32 / Chapter 2.2.1. --- Establishment of Adriamycin Adapted Osteosarcoma Cells / Chapter 2.2.1.1. --- Maintenance and Subculture of SaOS-2 Cell Line / Chapter 2.2.1.2. --- Storage of Cell Line / Chapter 2.2.1.3. --- Adriamycin Treatment / Chapter 2.2.2. --- KB-V1 Cell Culture / Chapter 2.2.3. --- Adriamycin Binding Assay / Chapter 2.2.4. --- P-glycoprotein Immunohistochemistry / Chapter 2.2.4.1. --- Sample and Control Preparation / Chapter 2.2.4.2. --- Immunohistochemical Procedures / Chapter 2.2.5. --- Thymidine Incorporation Assay / Chapter 2.2.5.1. --- Assay Procedures / Chapter 2.2.6. --- Catalase Assay / Chapter 2.2.6.1. --- Assay Procedures / Chapter 2.2.6.2. --- Unit Calculation / Chapter 2.2.7. --- Glutathione Peroxidase Assay / Chapter 2.2.7.1. --- Assay Procedures / Chapter 2.2.7.2. --- Unit Calculation / Chapter 2.2.8. --- Protein Determination / Chapter 2.3. --- Statistical Analysis --- p.45 / Chapter 3. --- RESULTS --- p.46 / Chapter 3.1. --- Clinical Study --- p.46 / Chapter 3.1.1. --- Patients Recruitment / Chapter 3.1.2. --- Correlation of Adriamycin Sensitivity to Tumour Necrosis / Chapter 3.1.3. --- Correlation of P-glycoprotein Expression to Tumour Necrosis / Chapter 3.1.4. --- Correlation of P-glycoprotein Expression to Adriamycin Sensitivity / Chapter 3.2. --- Effect of Adriamycin on Osteosarcoma Cells --- p.63 / Chapter 3.2.1. --- Adriamycin Sensitivity and P-glycoprotein Expression / Chapter 3.2.2. --- Thymidine Incorporation Rate / Chapter 3.2.3. --- Intracellular Concentration of Catalase / Chapter 3.2.4. --- Intracellular Concentration of Glutathione Peroxidase / Chapter 4. --- DISCUSSIONS --- p.71 / Chapter 4.1. --- Clinical Study --- p.71 / Chapter 4.1.1. --- Patients Recruitment / Chapter 4.1.2. --- Correlation between Adriamycin Sensitivity and Tumour Necrosis / Chapter 4.1.3. --- Correlation between P-glycoprotein Expression and Tumour Necrosis / Chapter 4.1.3.1. --- P-glycoprotein Is Induced During Chemotherapy / Chapter 4.1.3.2. --- P-glycoprotein Cannot Serve As a Prognostic Factor / Chapter 4.1.4. --- Correlation Between Adriamycin Sensitivity and P-glycoprotein Expression / Chapter 4.2. --- Effect of Adriamycin on Osteosarcoma Cells --- p.76 / Chapter 4.2.1. --- Adriamycin Sensitivity and P-glycoprotein Expression / Chapter 4.2.2. --- Proliferation Rate / Chapter 4.2.3. --- Antioxidative Enzymes Activities / Chapter 5. --- CONCLUSION --- p.82 / Chapter 6. --- FURTHER STUDY --- p.83 / Chapter 7. --- BIBLIOGRAPHY --- p.84 / Chapter 8. --- APPENDIX - SOLUTIONS PREPARATION --- p.93

Page generated in 0.0917 seconds